A phase II dose-ranging study of mirabegron in patients with overactive bladder

被引：0
|
作者：
Christopher R. Chapple
Vladimir Dvorak
Pjotr Radziszewski
Philip Van Kerrebroeck
Jean Jacques Wyndaele
Brigitte Bosman
Peter Boerrigter
Ted Drogendijk
Arwin Ridder
Ingrid Van Der Putten-Slob
Osamu Yamaguchi
机构：
[1] Sheffield Teaching Hospitals,Department of Urology, Royal Hallamshire Hospital
[2] Centrum ambulantní gynekologie a primární péce,Department of Urology
[3] Medical University Warsaw,Department Urology
[4] Maastricht University Medical Center,Department of Urology
[5] Antwerp University and Antwerp University Hospital,Division of Bioengineering and LUTD Research, School of Engineering
[6] Astellas Pharma Europe BV,undefined
[7] Nihon University,undefined
来源：
International Urogynecology Journal | 2013年 / 24卷
关键词：
β; -adrenoceptor agonist; Mirabegron; Overactive; Urinary bladder;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1447 / 1458
页数：11
相关论文
共 50 条
  • [41] EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study
    Ratziu, Vlad
    Rinella, Mary E.
    Neuschwander-Tetri, Brent A.
    Lawitz, Eric
    Denham, Douglas
    Kayali, Zeid
    Sheikh, Aasim
    Kowdley, Kris, V
    Desta, Taddese
    Elkhashab, Magdy
    DeGrauw, Jeffery
    Goodwin, Bryan
    Ahmad, Alaa
    Adda, Nathalie
    JOURNAL OF HEPATOLOGY, 2022, 76 (03) : 506 - 517
  • [42] A Comparative Study of Solifenacin, Mirabegron, and Their Combination as Bladder Relaxants in the Management of Overactive Bladder
    Kumar, Shailendra
    Tiwari, Vidushi
    Chaurasia, Dileep K.
    Kumar, Sudheer
    Mishra, Shirish
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (09)
  • [43] Re: Mirabegron for Overactive Bladder in Frail Patients 80 Years or Over (HOKUTO Study)
    Siegel, Cary
    JOURNAL OF UROLOGY, 2022, 208 (04): : 909 - 912
  • [44] New data on the combined treatment of solifenacin and mirabegron in patients with overactive bladder: SYNERGY study
    Alcantara Montero, A.
    ACTAS UROLOGICAS ESPANOLAS, 2018, 42 (01): : 70 - 71
  • [45] Dose-ranging study of an orlistat tablet formulation
    Schwartz, Susan M.
    Savastano, David M.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2018, 56 (10) : 476 - 481
  • [46] Phase II Dose-Ranging Trial of the Early Bactericidal Activity of PA-824
    Diacon, Andreas H.
    Dawson, Rodney
    du Bois, Jeannine
    Narunsky, Kim
    Venter, Amour
    Donald, Peter R.
    van Niekerk, Christo
    Erondu, Ngozi
    Ginsberg, Ann M.
    Becker, Piet
    Spigelman, Melvin K.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2012, 56 (06) : 3027 - 3031
  • [47] Efficacy and safety of tolterodine in patients with detrusor instability: a dose-ranging study
    Rentzhog, L
    Stanton, SL
    Cardozo, L
    Nelson, E
    Fall, M
    Abrams, P
    BRITISH JOURNAL OF UROLOGY, 1998, 81 (01): : 42 - 48
  • [48] A dose-ranging study of the behavioural effects of guarana
    Haskell, CF
    Kennedy, DO
    Milne, AL
    Wesnes, KA
    Scholey, AB
    JOURNAL OF PSYCHOPHARMACOLOGY, 2005, 19 (05) : A45 - A45
  • [49] Dose-ranging study of aripiprazole in patients with dementia of Alzheimer's disease
    Breder, C
    Swanink, R
    Marcus, R
    Kostic, D
    Iwamoto, T
    Carson, W
    McQuade, R
    NEUROBIOLOGY OF AGING, 2004, 25 : S190 - S190
  • [50] Study design and population pharmacokinetic analysis of a phase II dose-ranging study of interleukin-1 receptor antagonist
    Ogungbenro, Kayode
    Hulme, Sharon
    Rothwell, Nancy
    Hopkins, Stephen
    Tyrrell, Pippa
    Galea, James
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2016, 43 (01) : 1 - 12
12345